Shared molecular failure
Premature termination codons create a common translation problem across otherwise fragmented diseases.
Investors
A platform thesis.
Measured by evidence gates.
KritRNA is an early preclinical biotechnology company building suppressor-tRNA design and translation-system modelling capability from India.
Programmable modality
Suppressor tRNAs can be redesigned for selected stop codons and disease contexts.
Compounding evidence
Assay-labelled results can improve future candidate prioritisation.
Asset and platform optionality
Validated sequence families may support disease-wise licensing; computational engines may become licensable later.
Controlled material request
Start with fit, then move to diligence.
Investor material is shared manually after the founders review stage, mandate and strategic fit.
Review the evidence-gated programmes